COMMON STOCK PURCHASE WARRANT VYANT BIO, Inc.Common Stock Purchase Warrant • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories • Delaware
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, FOD Capital, LLC or its assigns (the “Holder”), located at 7009 Shrimp Rd., Suite 4, Key West, FL 33040, is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof or prior to 5:00 p.m. (New York City time) on February 23, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Vyant Bio, Inc. (the “Company”), up to 143,890 shares of the common stock of the Company, par value $.001 per share (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of common stock (the “Common Stock”) under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This warrant is being issued under the Agreement and Plan of Merger and Reorganization, dated as of August 21, 2020, as amended, (the “Merger Agreement”) by and among Cancer Genetic
VYANT BIO, INC. 2021 STOCK INCENTIVE PLANIncentive Stock Option Grant Agreement • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Vyant Bio, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
VYANT BIO, INC. 2020 STOCK INCENTIVE PLANNonqualified Stock Option Grant Agreement • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories • Delaware
This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between Vyant Bio, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).
VYANT BIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories • Minnesota
In consideration of the mutual covenants and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree, effective as of the Effective Time (as defined in that certain Agreement and Plan of Merger and Reorganization dated as of August 21, 2020, by and among the Company, StemoniX, Inc. and CGI Acquisition, Inc. (the “Merger Agreement”)), as follows:
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories
This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement (the “Employment Agreement”) by and between John Roberts (the “Executive”) and Vyant Bio, Inc. (F.K.A. Cancer Genetics, Inc.) (the “Company”) effective as of June 27, 2016 (the “Effective Date”) is effective as of the date set forth on the signature page hereof.
STOCK UNIT AWARD AGREEMENT VYANT BIO, INC.Stock Unit Award Agreement • April 5th, 2021 • Vyant Bio, Inc. • Services-medical laboratories • Delaware
This Stock Unit Award Agreement (the “Agreement” or “Award Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A, is entered into between Vyant Bio, Inc., a Delaware corporation (the “Company”), and the individual named in Exhibit A hereto (the “Awardee”).
